Astellas Pharma Global Development, Inc.
29 active trials across 10 therapeutic areas
29
Active Trials
14
Phase 1
10
Phase 2
8
Phase 3
10
Therapeutic Areas
Portfolio Concentration: 103% of active trials in Oncology
Oncology
30 active / 79 total
Solid Tumor (Advanced)
9 active
3 Ph3
24 total since 2015
Gastric Cancer
5 active
3 Ph3
5 total since 2015
Pancreatic Cancer
5 active
1 Ph3
5 total since 2015
Prostate Cancer
4 active
8 total since 2015
Bladder Cancer
3 active
1 Ph3
5 total since 2015
AML
1 active
11 total since 2015
NSCLC
1 active
6 total since 2015
Non-Hodgkin Lymphoma
1 active
3 total since 2015
ALL
1 active
3 total since 2015
Ovarian Cancer
0 active
2 total since 2015
Hematologic Malignancies
0 active
1 total since 2015
Endometrial Cancer
0 active
1 total since 2015
Squamous Cell Carcinoma
0 active
1 total since 2015
Hepatocellular Carcinoma
0 active
1 total since 2015
Lung Cancer (General)
0 active
1 total since 2015
MDS
0 active
1 total since 2015
Renal Cell Carcinoma
0 active
1 total since 2015
Immunology
6 active / 17 total
Women's Health
2 active / 6 total
Cardiovascular
1 active / 4 total
Renal
1 active / 1 total
CNS
0 active / 8 total
Urology
0 active / 5 total
Infectious Disease
0 active / 2 total
Ophthalmology
0 active / 1 total
Respiratory
0 active / 1 total
Click an indication to see competitive landscape (all sponsors in that indication).
Data: ClinicalTrials.gov (2015+)